Last checked at 27 Sep 2018 13:03
| (AIM: SAR) | 27 September 2018 |
This announcement contains inside information for the purposes of Article 7 of Regulation 596/2014
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
Notice of Final Results for the Year Ended 30 June 2018
Sareum Holdings plc (AIM: SAR), the specialist in small molecule drug development, announces that it will release its results for the full year ended 30 June 2018 on or around Monday, 1 October 2018.
For further information, please contact:
| Sareum Holdings plc |
|
| Tim Mitchell | 01223 497 700 |
| WH Ireland Limited (Nominated Adviser) | |
| Chris Fielding / James Sinclair-Ford | 020 7220 1666 |
| Hybridan LLP (Broker) |
|
| Claire Noyce | 020 3764 2341 |
| Citigate Dewe Rogerson (Media enquiries) |
|
| Shabnam Bashir/ Mark Swallow/ David Dible | 020 7638 9571 |
About Sareum Holdings plc
Sareum is a drug discovery and development company delivering targeted small molecule therapeutics, focusing on cancer and autoimmune disease. The Company generates value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum's leading clinical-stage programme, SRA737, a novel Checkpoint kinase 1 (Chk1) inhibitor licensed to NASDAQ-listed Sierra Oncology, is in Phase 2 clinical trials targeting ovarian and other advanced cancers. The key role of Chk1 in cancer cell replication and DNA damage repair suggests that SRA737 may have broad application as a targeted therapy in combination with other oncology and immune-oncology drugs in genetically defined patients.
Sareum is also advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) /Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases and cancers. TYK2 and JAK1 have roles in pro-inflammatory responses in autoimmune diseases (e.g. psoriasis, rheumatoid arthritis, inflammatory bowel diseases and lupus) and tumour cell proliferation in certain cancers (e.g. T-cell acute lymphoblastic leukaemia and some solid tumours). The Company is targeting first human clinical trials in each indication in 2020.
The Company also has an Aurora+FLT3 inhibitor targeting haematological cancers, which is at the preclinical development stage.
Sareum Holdings plc is listed on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit www.sareum.co.uk
- Ends -